BIBR-1048 Boehringer Ingelheim

Current Opinion in Investigational Drugs

Volumn 3, Issue 6, 2002, Pages 905-907

  Mungall, Dennis ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; BIBR 1048BS; BIBR 1048MS; BIBR 953ZW; DABIGATRAN ETEXILATE; MELAGATRAN; PLACEBO; PRODRUG; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN;

BLEEDING; BLOOD CLOTTING PARAMETERS; BRAIN ISCHEMIA; CLINICAL TRIAL; CORRELATION ANALYSIS; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESEARCH; DRUG SYNTHESIS; DRUG TOLERABILITY; HEART ATRIUM FIBRILLATION; HEMATOMA; HUMAN; INHIBITION KINETICS; MULTIPLE DRUG DOSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; STROKE; STRUCTURE ACTIVITY RELATION; THROMBOEMBOLISM; VEIN THROMBOSIS;

ANIMALS; BENZIMIDAZOLES; BRAIN ISCHEMIA; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; HUMANS; PRODRUGS; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0036628436     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. 331881 Drug development pipeline: Terbogrel, BIBR-1048 and ion channel blockers. Boehringer Ingelheim GmbH Company Communication 1999 July 14
2. 377656 AstraZeneca R&D pipeline: NCEs. AstraZeneca Plc Company World Wide Web Site 2000 August 01
3. 414268 Identification and in vitro characterization of BIBR 953 ZW, a novel synthetic low molecular weight direct thrombin inhibitor. Stassen JM, Hauel NH, Nar H, Ries UJ, Priepke HWM, Wienen W Thromb Haemost 2001 6-12 July Abs 755P
4. 414274 Antithrombotic effects of melagartan, a new direct thrombin inhibitor in an ex vivo pig model of arterial thrombosis. Osende J, Zaman A, Rodriguez O, Carlsson S, Fuster V, Badimon JJ Thromb Haemost 2001 6-12 July Abs 757P
5. 414278 Effects of the direct thrombin inhibitor BIBR953ZW and its orally active prodrug BIBR1048MS on experimentally-induced clot formation and template bleeding time in rats. Wienen W, Nar H, Ries UJ, Priepke HWM, Hauel NH, Stassen JM Thromb Haemost 2001 6-12 July Abs 761P
6. 414296 Ex vivo anticoagulant activity of BIBR953ZW, a novel sythethic direct thrombin inhibitor and its prodrug BIBR1048 MS in different animal species. Stassen JM, Hauel NH, Nar H, Ries UJ, Priepke HMW, Wienen W Thromb Haemost 2001 6-12 July Abs 763P
7. 414779 International Society on Thrombosis and Haemostasis - XVIIIth Congress (Part III) - Overnight Report, Paris, France. So L IDDB Meeting Report 2001 July 6-12
8. 415870 International Society on Thrombosis and Haemostasis - XVIIIth Congress (Part VIII), Paris, France. IDdb author IDDB Meeting Report 2001 July 6-12
9. 415884 Drug development: BIBR-953ZW. Boehringer Ingelheim Pharma KG Company Communication 2001 July 09
10. 415891 Pharmacokinetics of the synthetic direct thrombin inhibitor BIBR 953 ZW in different animal species. Busch U, Schmid J Thromb Haemost 2001 6-12 July Abs P766
11. 418740 Pharmacodynamics of the synthetic direct thrombin inhibitor BIBR-953ZW in healthy subjects. Stassen JM, Rathgen K, Zimmermann R, Wienen W, Stangier J Thromb Haemost 2001 6-12 July Abs OC160
12. 418741 Antithrombotic effects of the direct thrombin inhibitor BIBR-953ZW and its orally active prodrug BIBR1048MS in a model of venous thrombosis in rabbits. Wienen W, Nar H, Ries UJ, Priepke HWM, Hauel NH, Stassen JM Thromb Haemost 2001 6-12 July Abs OC853
13. 446554 Boehringer Ingelheim Annual Press Conference. Boehringer Ingelheim Corp Company Presentation 2002 April 09